Prolocor Announces $1.7 Million in Bridge Funding
Summary
Dr. Clay Heighten, Managing Partner at GPG Ventures, remarked, "We are encouraged by the impressive progress that the team at Prolocor is making. In addition, our Co-Founder and CSO Dr. David Schneider and his lab team have confirmed the precision, accuracy, and specificity of the unique pCFG test. The prognostic tool being developed by Prolocor will help guide treatment decisions, effectively matching the intensity of therapy with the risk of events.Founded by a team that deeply understands thrombosis and cardiovascular disease, Prolocor is building its strategy around platelet FcRIIa and embarking on a journey to commercialize an innovative precision diagnostic test that quantifies FcRIIa on the surface of platelets. For more information on Prolocor, please visit the companys website at www.prolocor.com and follow us on LinkedIn.This press release contains forward-looking statements as defined in the Private Securities Litigation Reform Act of 1995, as amended. These risks and uncertainties include among other things, Prolocors planned level of revenues and capital expenditures, Prolocors available cash and its ability to obtain additional funding, the uncertainties inherent in research and development, future clinical data and analysis, including post marketing, decisions by regulatory authorities regarding whether and when to approve any device or application that may be filed for any such product candidates and other matters that could affect the availability or commercial potential of such product candidates, the fact that product candidates if approved may not be commercially successful, the future approval and commercial success of therapeutic alternatives, Prolocors ability to benefit from external growth opportunities, to complete related transactions and/or obtain regulatory clearances, and risks associated with intellectual property.